Lupin is currently trading at Rs. 909.60, up by 17.85 points or 1.93% from its previous closing of Rs. 891.55 on the BSE.
The scrip opened at Rs. 894.00 and has touched a high and low of Rs. 911.65 and Rs. 888.00 respectively. So far 51,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 946.35 on 11-Oct-2013 and a 52 week low of Rs. 569.00 on 01-Mar-2013.
Last one week high and low of the scrip stood at Rs. 898.55 and Rs. 864.00 respectively. The current market cap of the company is Rs. 40,784 crore.
The promoters holding in the company stood at 46.78% while Institutions and Non-Institutions held 43.52% and 9.69% respectively.
Pharma Major Lupin’s US subsidiary-Lupin Pharmaceuticals Inc. has launched Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300mg (base) / 150mg / 300mg in the US after the US District Court for the District of Delaware ruled that the Lupin’s generic version of Trizivir did not infringe on patents. Lupin had earlier received approval for the same.
Lupin’s Abacavir Sulfate, Lamivudine Zidovudine 300mg (Base)/150mg/300mg Tablets are the AB?rated generic equivalent of ViiV Healthcare’s (ViiV) Trizivir Tablets, 300mg (base) / 150mg / 300mg and are indicated in combination with other antiretrovirals or alone for the treatment of HIV?1 infection. Lupin is the first applicant to file an ANDA for Trizivir Tablets and as such is entitled to 180 days of marketing exclusivity.
Trizivir Tablets, 300mg (base) / 150mg / 300mg had annual U.S sales of approximately $ 111.6 million (IMS MAT Sep, 2013).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |